Literature DB >> 29966099

Targeting the Myofibroblast in Pulmonary Fibrosis.

Alexander V Misharin1, G R Scott Budinger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29966099     DOI： 10.1164/rccm.201806-1037ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging.

Authors:  Kosuke Kato; Naomi J Logsdon; Yoon-Joo Shin; Sunny Palumbo; Adam Knox; Joseph D Irish; Skye P Rounseville; Sydney R Rummel; Mohamed Mohamed; Kareem Ahmad; Johnny M Trinh; Deepali Kurundkar; Kenneth S Knox; Victor J Thannickal; Louise Hecker
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

2.  M2 macrophages have unique transcriptomes but conditioned media does not promote profibrotic responses in lung fibroblasts or alveolar epithelial cells in vitro.

Authors:  Elissa M Hult; Stephen J Gurczynski; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-07-07       Impact factor: 6.011

3.  Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy.

Authors:  Jiwei Hou; Qijian Ji; Jie Ji; Shenghong Ju; Chun Xu; Xueqing Yong; Xiaoxuan Xu; Mohd Muddassir; Xiang Chen; Jinbing Xie; Xiaodong Han
Journal:  Theranostics       Date:  2021-01-09       Impact factor: 11.556

4.  Fructose-1,6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts.

Authors:  Henrique Bregolin Dias; Jarbas Rodrigues de Oliveira; Márcio Vinícius Fagundes Donadio; Shioko Kimura
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.